Article
Successful phase 2 trial, Aerie Pharmaceuticals, Inc.’s dry eye candidate advancing to phase 3
Author(s):
David Wirta, MD, Medical Director for the Eye Research Foundation, Inc., presents the data of Aerie Pharmaceuticals, Inc.’s novel dry eye product candidate, AR-15512 (0.003%). The successful phase 2 results has propelled the product into phase 3 trials.
Video Player is loading.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
Setting the stage in LA: Neda Shamie, MD, on the 19th Annual Controversies in Modern Eye Care
World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
EnVision Summit 2025: Glaucoma with co-existing ocular co-morbidities
AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
EnVision Summit 2025: Ergonomics in the operating room
Related Content
